• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.47% Nasdaq Up0.39%

    Synta Pharmaceuticals Corp. (SNTA)

    2.96 Up 0.07(2.42%) Apr 21, 4:00PM EDT
    |After Hours : 2.96 0.00 (0.00%) Apr 21, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Synta Pharmaceuticals Corp.
    45 Hartwell Avenue
    Lexington, MA 02421
    United States - Map
    Phone: 781-274-8200
    Fax: 781-274-8228
    Website: http://www.syntapharma.com

    Index Membership:N/A
    Full Time Employees:110

    Business Summary 

    Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its lead oncology drug candidate includes ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma. The company’s product pipeline also comprises Hsp90-inhibitor Drug Conjugate, a novel, proprietary small molecule cancer drug development program; Elesclomol, a mitochondria-targeting agent that is in Phase II clinical trial for ovarian cancer; and CRACM ion channel inhibitors and IL-12/23 inhibitors for the treatment of inflammatory diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Synta Pharmaceuticals Corp.

    Corporate Governance 
    Synta Pharmaceuticals Corp.’s ISS Governance QuickScore as of Apr 1, 2015 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Keith R. Gollust , 69
    Exec. Chairman, Chairman of Exec. Committee, Member of Audit Committee and Member of Compensation Committee
    Dr. Vojo Vukovic M.D., Ph.D., 48
    Chief Medical Officer and Sr. VP
    Ms. Anne Clem Whitaker , 48
    Chief Exec. Officer, Pres and Director
    Dr. Lan Bo Chen Ph.D., 71
    Mr. Marc R. Schneebaum , 61
    Chief Financial Officer and Sr. VP
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders